The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global structural heart imaging market reached a value of US$ 16.2 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 30.4 Billion by 2027 exhibiting a growth rate (CAGR) of 10.60% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Structural heart imaging (SHI) is a special technique, which is extensively deployed in the healthcare industry for screening and examining the heart at the molecular level. This procedure includes the utilization of light reflection for producing the interior element images and creating a 2-dimensional cross-section analysis to get a clarified and accurate diagnosis. It is further used for enabling and assisting professionals while performing various operative procedures, such as locating the blockages and pathways for insertion by minimizing the risk of interference.
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
The escalating prevalence of various congenital, cardiac diseases and lifestyle-induced ailments, such as obesity, diabetes, and high blood pressure due to excessive alcohol consumption and unhealthy eating habits, is one of the primary factors majorly driving the global heart imaging market toward the growth. Furthermore, the rising health consciousness amongst the consumers is positively influencing the market across the globe. In addition to this, the widespread adoption of SHI for addressing various heart conditions, such as non-valvular and valvular heart diseases, with the support of high precision and resolution cameras and sensors is considerably contributing to the market growth. Moreover, the introduction of transcatheter aortic valve replacement (TAVR) for operating heart diseases interventions by ensuring instant recovery of consumers post-surgery is promoting the growth of the market. Other than this, the rising investments in research and development (R&D) activities for introducing advanced structural heart imaging and cardiac systems is creating a positive outlook for the market. In line with this, the market is further being driven by the numerous initiatives undertaken by the governments of various nations for improving the healthcare infrastructure to ensure patients wellness.
IMARC Group provides an analysis of the key trends in each sub-segment of the global structural heart imaging market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on imaging modality, procedure type, application and end user.
Breakup by Imaging Modality:
Breakup by Procedure Type:
Breakup by Application:
To get more information about this market, Request Sample
Breakup by End User:
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Boston Scientific Corporation, Circle Cardiovascular Imaging Inc., Edwards Lifesciences Corporation, Integer Holdings Corporation, Koninklijke Philips N.V., Lepu Medical Technology (Beijing) Co. Ltd., LivaNova PLC, Medtronic plc, Pie Medical Imaging B.V. and Siemens Healthcare GmbH.
|Base Year of the Analysis||2021|
|Segment Coverage||Imaging Modality, Procedure Type, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Boston Scientific Corporation, Circle Cardiovascular Imaging Inc., Edwards Lifesciences Corporation, Integer Holdings Corporation, Koninklijke Philips N.V., Lepu Medical Technology (Beijing) Co. Ltd., LivaNova PLC, Medtronic plc, Pie Medical Imaging B.V. and Siemens Healthcare GmbH.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global structural heart imaging market was valued at US$ 16.2 Billion in 2021.
We expect the global structural heart imaging market to exhibit a CAGR of 10.60% during 2022-2027.
The rising prevalence of cardiac diseases, coupled with the extensive application of structural heart
imaging process for diagnosing various heart conditions with high precision and resolution
cameras, is primarily driving the global structural heart imaging market.
The sudden outbreak of the COVID-19 pandemic has led to the growing demand for structural heart
imaging as the COVID-19 infection affects the cardiovascular system by increasing the risk of heart
failure in patients with pre-existing cardiac conditions.
Based on the imaging modality, the global structural heart imaging market can be bifurcated into
echocardiogram and angiogram. Currently, echocardiogram accounts for the majority of the total
On a regional level, the market has been classified into North America, Europe, Asia-Pacific, Middle
East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global structural heart imaging market include Abbott Laboratories,
Boston Scientific Corporation, Circle Cardiovascular Imaging Inc., Edwards Lifesciences Corporation,
Integer Holdings Corporation, Koninklijke Philips N.V., Lepu Medical Technology (Beijing) Co. Ltd.,
LivaNova PLC, Medtronic plc, Pie Medical Imaging B.V., and Siemens Healthcare GmbH.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at